Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
October 2021
in “Journal of The American Academy of Dermatology”
TLDR Baricitinib is effective and safe for treating severe alopecia areata.
The study assessed the effectiveness and safety of baricitinib, an oral Janus kinase inhibitor, in 110 adults with severe alopecia areata. Patients were randomized to receive either a placebo or baricitinib at doses of 1 mg, 2 mg, or 4 mg daily. The 1 mg dose was discontinued due to lower efficacy. At week 36, 33.3% of patients in the 2 mg group and 51.9% in the 4 mg group achieved a Severity of Alopecia Tool (SALT) score of ≤20, significantly more than the 3.6% in the placebo group. The study also found significant improvements in Clinician-Reported Outcome measures for scalp, eyebrow, and eyelash hair loss with baricitinib. Safety outcomes were acceptable, with no serious adverse events or deaths. Despite the small sample size, the study concluded that baricitinib is effective and safe for treating alopecia areata, warranting further phase 3 trials.
View this study on jaad.org →
Cited in this study
research Treatment of severe alopecia areata with baricitinib
Baricitinib helped a woman with severe hair loss regrow almost all her hair without side effects.
research Alopecia areata: A multifactorial autoimmune condition
Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Alopecia areata
Alopecia areata is an autoimmune condition causing hair loss, influenced by genetics, stress, and diet, and may be prevented by a high soy oil diet.
research Tofacitinib for the treatment of alopecia areata and variants in adolescents
Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
research Health-related quality of life (HRQoL) among patients with alopecia areata (AA): A systematic review
People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.
research Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
Ruxolitinib effectively regrows hair in most patients with severe hair loss.
research Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research Alopecia areata and health-related quality of life: a systematic review and meta-analysis
Alopecia areata significantly lowers the quality of life, especially in emotional and mental health aspects.
research Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.
research The autoimmune basis of alopecia areata: A comprehensive review
research Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis
A man with severe hair loss and skin disease regrew his hair with no side effects after taking tofacitinib.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
Related
research Sensitive scalp: An epidemiologic study in patients with hair loss
Many people with hair loss, especially those with telogen effluvium and alopecia areata, often have a sensitive scalp.
research Twenty nail dystrophy with alopecia areata in an atopic child
A child with rough nails also had hair loss and allergies.